BALAXI PHARMACEUTICALS share news, announcements and annual reports
NSE: BALAXIPharmaceuticals & BiotechnologySmall Cap
BALAXI PHARMACEUTICALS LIMITED · Formerly Balaxi Ventures · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2015
Last close ₹19.15down ₹0.56 (2.84%)
Share price at the NSE close on 30 Oct 2026. Previous close ₹19.71.
30 Oct: open ₹19.99, high ₹19.99, low ₹18.70
52-week range of traded prices to 30 Oct 2026
₹15.20Low, 27 Mar 2026₹43.85High, 4 Nov 2025
- Next results date: the board meets on 12 Nov 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,722nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 43.61
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.42
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 1.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.22
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 21,37768.9% delivered
BALAXI PHARMACEUTICALS has 466 announcements on record, routine notices left out; 2 in the 30 days to 31 Oct 2026, the latest on 27 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.BALAXI PHARMACEUTICALS quarterly results
Nov12Thu
The board meets on 12 Nov 2026 to consider financial results and other business matters
Notice filed 27 Oct 2026
BALAXI PHARMACEUTICALS annual reports, presentations and earnings calls
The company's own documents, latest first.BALAXI PHARMACEUTICALS financials, year by year
Annual reports11
- Annual report, year to Mar 202631 Jul 2026
- Annual report, year to Mar 202531 Jul 2025
- Annual report, year to Mar 202431 Jul 2024
- Annual report, year to Mar 20231 Aug 2023, a zip file
- Annual report, year to Mar 202218 Jun 2022, a zip file
6 earlier reports
- Annual report, year to Mar 202130 Jul 2021, a zip file
- Annual report, year to Mar 202019 Aug 2020, a zip file
- Annual report, year to Mar 201919 Sep 2019, a zip file
- Annual report, year to Mar 201820 Sep 2018, a zip file
- Annual report, year to Mar 20171 Oct 2017, a zip file
- Annual report, year to Mar 20163 Oct 2016, a zip file
Investor presentations25
- Investor Presentation6 Aug 2026
- Investor Presentation29 May 2026
- Investor Presentation29 Jan 2026
- Investor Presentation14 Nov 2025
- Investor Presentation8 Aug 2025
20 earlier presentations
- Investor Presentation7 Jun 2025
- Investor Presentation13 Feb 2025
- Investor Presentation13 Nov 2024
- Investor Presentation5 Aug 2024
- Investor Presentation30 May 2024
- Investor Presentation9 Feb 2024
- Investor Presentation2 Nov 2023
- Investor Presentation3 Aug 2023
- Investor Presentation29 May 2023
- Investor Presentation1 Feb 2023
- Investor Presentation5 Nov 2022
- Investor Presentation2 Aug 2022
- Investor Presentation24 Jun 2022
- Investor Presentation15 Feb 2022
- Investor Presentation2 Nov 2021
- Investor Presentation19 Jul 2021
- Investor Presentation26 May 2021
- Investor Presentation19 Jan 2021
- Investor Presentation12 Oct 2020
- Corporate Presentation7 Oct 2020
Earnings calls5
- Transcript of Analysts/Institutional Investor Meet/Con. Call15 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call9 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call9 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call23 Aug 2022
- Transcript of Earnings Call held on 22nd January 20212 Feb 2021
BALAXI PHARMACEUTICALS share news and announcements
Newest first. Page 1 of 10.
Oct 2026
Sep 2026
Aug 2026
24 Aug · Management
10 Aug · Corrigendum
5 Aug · Board meeting
5 Aug · Results
Jul 2026
Jun 2026
24 Jun · Legal
Exchange has sought clarification from BALAXI PHARMACEUTICALS LIMITED for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted in XBRL with discrepancies. The response of the Company is awaited.
May 2026
28 May · Board meeting
28 May · Results
Apr 2026
9 Apr · Legal
The exchange asked on 8 Apr 2026
2 Apr · Rating
Mar 2026
25 Mar · Board meeting
Jan 2026
28 Jan · Business
28 Jan · Results
Nov 2025
14 Nov · Rating
11 Nov · Updates
11 Nov · Business
11 Nov · Results
Aug 2025
25 Aug · Meeting
5 Aug · Results
5 Aug · Business
5 Aug · Board meeting
Jul 2025
31 Jul · Updates
31 Jul · Meeting
May 2025
30 May · Business
30 May · Results
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 5 Aug 2026Resultsup 0.58%+0.4 pts vs Nifty 500market median −0.7% · five sessions −1.6% (−1.5 pts vs Nifty 500) · volume 4.3× usual · The announcement
- 29 May 2026Resultsup 4.97%+6.3 pts vs Nifty 500market median −0.7% · five sessions −1.3% (+0.8 pts vs Nifty 500) · volume 1.4× usual · The announcement
- 2 Apr 2026Credit ratingup 12.34%+12.3 pts vs Nifty 500market median 0.0% · five sessions +22.1% (+16.9 pts vs Nifty 500) · volume 1.8× usual · delivery −28.8 pts against usual · The announcement
- 28 Jan 2026Resultsup 3.50%+2.3 pts vs Nifty 500market median −0.7% · five sessions −2.1% (−2.1 pts vs Nifty 500) · volume 0.3× usual · delivery +7.7 pts against usual · The announcement
- 14 Nov 2025Credit ratingdown 3.95%−4.0 pts vs Nifty 500market median 0.0% · five sessions −7.7% (−8.3 pts vs Nifty 500) · volume 1.9× usual · delivery +2.4 pts against usual · The announcement
- 11 Nov 2025Resultsdown 4.19%−4.6 pts vs Nifty 500market median −0.7% · five sessions −13.9% (−15.4 pts vs Nifty 500) · volume 3.1× usual · delivery +17.8 pts against usual · The announcement
- 6 Aug 2025Resultsup 0.95%+1.5 pts vs Nifty 500market median −0.7% · five sessions +2.9% (+3.9 pts vs Nifty 500) · volume 1.9× usual · delivery −12.6 pts against usual · The announcement
- 30 May 2025Resultsup 0.04%+0.3 pts vs Nifty 500market median −0.7% · five sessions +2.1% (+1.8 pts vs Nifty 500) · volume 2.3× usual · delivery −4.4 pts against usual · The announcement
- 10 Feb 2025Resultsdown 2.26%−1.0 pts vs Nifty 500market median −0.7% · five sessions −13.5% (−8.8 pts vs Nifty 500) · volume 0.4× usual · delivery +1.7 pts against usual · The announcement
- 18 Nov 2024Credit ratingup 0.68%+1.0 pts vs Nifty 500market median 0.0% · five sessions +2.2% (−0.4 pts vs Nifty 500) · volume 0.2× usual · delivery +21.8 pts against usual · The announcement
20 earlier announcements
- 5 Nov 2024Resultsup 1.87%+1.2 pts vs Nifty 500market median −0.7% · five sessions −8.2% (−8.5 pts vs Nifty 500) · volume 2.1× usual · delivery −28.7 pts against usual · The announcement
- 5 Nov 2024Board or managers changedup 1.87%+1.2 pts vs Nifty 500market median 0.0% · five sessions −8.2% (−8.5 pts vs Nifty 500) · volume 2.1× usual · delivery −28.7 pts against usual · The announcement
- 2 Aug 2024Resultsup 0.19%+1.2 pts vs Nifty 500market median −0.7% · five sessions −5.9% (−2.5 pts vs Nifty 500) · volume 2.0× usual · delivery −18.0 pts against usual · The announcement
- 29 May 2024Resultsdown 3.73%−3.1 pts vs Nifty 500market median −0.7% · five sessions −31.1% (−26.1 pts vs Nifty 500) · volume 3.2× usual · delivery −12.0 pts against usual · The announcement
- 9 May 2024Board or managers changedup 0.97%+2.7 pts vs Nifty 500market median 0.0% · five sessions +6.9% (+6.7 pts vs Nifty 500) · volume 1.5× usual · delivery −3.7 pts against usual · The announcement
- 8 May 2024Board or managers changedup 0.20%−0.1 pts vs Nifty 500market median 0.0% · five sessions +2.5% (+2.2 pts vs Nifty 500) · volume 0.5× usual · delivery −19.0 pts against usual · The announcement
- 6 May 2024Board or managers changedup 1.23%+1.7 pts vs Nifty 500market median 0.0% · five sessions +0.1% (+2.4 pts vs Nifty 500) · volume 0.6× usual · delivery −11.3 pts against usual · The announcement
- 9 Feb 2024Resultsup 19.99%+20.1 pts vs Nifty 500market median −0.7% · five sessions +25.4% (+25.2 pts vs Nifty 500) · volume 21.9× usual · delivery −27.2 pts against usual · The announcement
- 2 Nov 2023Resultsdown 1.56%−2.5 pts vs Nifty 500market median −0.7% · five sessions −4.0% (−7.2 pts vs Nifty 500) · volume 1.0× usual · delivery −20.8 pts against usual · The announcement
- 16 Aug 2023Credit ratingdown 1.23%−1.4 pts vs Nifty 500market median 0.0% · five sessions −1.6% (−2.1 pts vs Nifty 500) · volume 0.4× usual · delivery −10.0 pts against usual · The announcement
- 3 Aug 2023Resultsdown 7.04%−6.5 pts vs Nifty 500market median −0.7% · five sessions −7.0% (−7.8 pts vs Nifty 500) · volume 6.0× usual · delivery −1.4 pts against usual · The announcement
- 29 May 2023Resultsup 5.09%+4.6 pts vs Nifty 500market median −0.7% · five sessions −7.9% (−8.6 pts vs Nifty 500) · volume 1.3× usual · delivery −11.4 pts against usual · The announcement
- 1 Feb 2023Resultsdown 3.28%−2.7 pts vs Nifty 500market median −0.7% · five sessions −9.0% (−8.8 pts vs Nifty 500) · volume 3.3× usual · delivery −19.7 pts against usual · The announcement
- 7 Nov 2022Resultsup 1.32%+0.8 pts vs Nifty 500market median −0.7% · five sessions −1.4% (−2.2 pts vs Nifty 500) · volume 3.3× usual · The announcement
- 19 Sep 2022Board or managers changeddown 4.73%−5.1 pts vs Nifty 500market median 0.0% · five sessions −6.7% (−5.5 pts vs Nifty 500) · volume 0.4× usual · The announcement
- 23 May 2022Dividendup 6.91%+7.3 pts vs Nifty 500market median 0.0% · five sessions +0.4% (+0.5 pts vs Nifty 500) · volume 1.3× usual · delivery −13.9 pts against usual · The announcement
- 9 Feb 2022Resultsdown 3.17%−4.2 pts vs Nifty 500market median −0.7% · five sessions −9.3% (−8.9 pts vs Nifty 500) · volume 1.1× usual · delivery +1.3 pts against usual · The announcement
- 19 Jul 2021Resultsup 5.00%+5.9 pts vs Nifty 500market median −0.7% · five sessions −1.9% (−1.4 pts vs Nifty 500) · volume 1.9× usual · delivery +22.5 pts against usual · The announcement
- 22 Jul 2020Resultsup 5.00%+5.3 pts vs Nifty 500market median −0.7% · five sessions +27.6% (+26.8 pts vs Nifty 500) · volume 5.0× usual · delivery −28.3 pts against usual · The announcement
- 14 Feb 2020Resultsdown 4.74%−4.2 pts vs Nifty 500market median −0.7% · five sessions −2.5% (−1.9 pts vs Nifty 500) · volume 0.7× usual · delivery −8.8 pts against usual · The announcement
BALAXI PHARMACEUTICALS results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
The latest 30. Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Goodwill bought | Year to Mar 2026 | Consolidated | 5.93 | 5.93 | 0.0% | 28 May 2026 | 30 Jun 2026 |
| Financial liabilities due within a year | At Mar 2026 | Consolidated | 33.59 | 54.64 | +62.7% | 28 May 2026 | 30 Jun 2026 |
| Adjustments from profit to cash | Year to Mar 2026 | Consolidated | −5.08 | −5.07 | +0.1% | 28 May 2026 | 30 Jun 2026 |
| Goodwill bought | Year to date to Mar 2026 | Consolidated | 5.93 | 5.93 | 0.0% | 28 May 2026 | 30 Jun 2026 |
| Other comprehensive income | Quarter to Mar 2026 | Consolidated | −8.44 | 8.44 | +200.0% | 28 May 2026 | 30 Jun 2026 |
| Other liabilities due within a year | At Mar 2026 | Consolidated | 5.27 | 5.42 | +2.9% | 28 May 2026 | 30 Jun 2026 |
| Adjustments from profit to cash | Year to date to Mar 2026 | Consolidated | −5.08 | −5.07 | +0.1% | 28 May 2026 | 30 Jun 2026 |
| Cash from operations | Year to date to Mar 2026 | Consolidated | −4.50 | −4.50 | +0.1% | 28 May 2026 | 30 Jun 2026 |
| Cash from operations | Year to Mar 2026 | Consolidated | −4.50 | −4.50 | +0.1% | 28 May 2026 | 30 Jun 2026 |
| Lease payments | Year to Mar 2026 | Consolidated | 0.10 | 0.10 | +0.3% | 28 May 2026 | 30 Jun 2026 |